Bengaluru-based medtech startup Ayati Devices has raised Rs 15 crore in a Pre-Series A funding round led by Inflexor Ventures, its first institutional funding round. The Ayati Devices funding will be used to accelerate commercialisation, expand into international markets, strengthen manufacturing capabilities and increase investment in AI-driven diagnostics.
Founded in 2019 by Nishant Kathpal and incubated at IIT Bombay’s Society for Innovation and Entrepreneurship (SINE), Ayati Devices builds diagnostic technology focused on diabetic foot complications and peripheral vascular disease. The company says its devices have already been deployed across 30 countries, with more than 10,000 units in use at leading healthcare institutions.
What Does Ayati Devices’ New Funding Mean for Indian Medtech?
The Rs 15 crore Pre-Series A round, led by Inflexor Ventures, is a signal that early-stage investors continue to back India’s medtech and diagnostics sector even as broader startup funding activity has moderated in 2026. Ayati’s focus on diabetic foot and peripheral vascular disease diagnostics addresses a large, underserved market: India has one of the highest diabetic populations globally, and diabetic foot complications are a leading cause of preventable amputations.
The company plans to channel the fresh capital into scaling manufacturing and deepening its use of artificial intelligence in diagnostic interpretation, a trend increasingly common among Indian medtech startups looking to differentiate through AI-assisted clinical decision support rather than hardware alone.
How Does This Fit India’s Broader Startup Funding Trends?
Ayati’s raise comes in a week that also saw Lightspeed India lead a $9 million seed round in deep-tech startup Discovered Materials, and follows a first week of August in which 22 Indian startups collectively raised about $274 million. Investors are increasingly favouring companies with clear commercialisation paths and export potential, both of which Ayati has demonstrated through its 30-country deployment footprint.
For India’s broader digital health and medtech ecosystem, deals like this reinforce that specialised, IP-driven hardware-plus-software startups are attracting capital even as generalist consumer-tech funding has cooled.
Industry Reaction and Expert Commentary
Inflexor Ventures, which led the round, has positioned the investment within its broader pre-Series A and Series A strategy; the fund recently announced a Rs 400 crore first close of its Rs 1,250 crore Fund III, backed by institutional investors including HDFC AMC. That fund is explicitly focused on backing scalable, technology-led Indian startups, of which Ayati’s AI-enabled diagnostics platform is a representative example.
What Happens Next?
Ayati Devices is expected to use the funding to expand its international market presence beyond its current 30-country footprint, ramp up manufacturing capacity, and continue R&D on AI-based diagnostic algorithms. Investors and industry watchers will be tracking whether the company can convert this institutional backing into a larger Series A round as it scales revenue over the next 12-18 months.
Frequently Asked Questions
How much funding did Ayati Devices raise?
Ayati Devices raised Rs 15 crore in a Pre-Series A round led by Inflexor Ventures, marking the Bengaluru-based startup’s first institutional funding.
What does Ayati Devices build?
Ayati Devices makes diagnostic technology for diabetic foot complications and peripheral vascular disease, with devices deployed across more than 30 countries and over 10,000 units in clinical use.
Who led the Ayati Devices funding round?
The round was led by Inflexor Ventures, a venture capital firm focused on pre-Series A and Series A technology startups in India.
Leave a comment